Introduction

Erythema multiforme (EM) can feel overwhelming to patients and confusing for clinicians, particularly because of how differently it presents and how little is published about quality of life (QoL) in this condition.

When patients with EM describe their experiences, they consistently report a burden that goes well beyond visible lesions. The painful skin eruptions and occasional oral or ocular involvement interfere with eating, speaking and sometimes even basic nutrition, while the fear of recurrences can create ongoing anxiety.^1,2 Research shows that the condition is most often linked to Herpes Simplex virus or Mycoplasma pneumoniae infections, though medications and other triggers are also implicated.^1,4 Treatment may help to control flare-ups, but outcomes are highly variable, and patients often feel frustrated with the unpredictability of their disease.^3,4 Despite this, formal studies that measure QoL in EM are rare, and when they do exist, they are typically case reports or small observational studies.^5–7

What we do know, though, is enough to highlight that EM is not just a rash — it is a condition that can seriously disrupt daily life.  By combining available clinical descriptions, treatment information and patient-reported outcome (PRO) data, we can form a clearer picture of life with EM.

Symptoms

EM is an acute immune-mediated skin disorder recognised by its distinctive “target” lesions — circular red and purple rings that often appear on the hands, feet, and sometimes the face. These lesions typically last for at least one week and often remain for two to four weeks.^1,2 Although most cases spare the mucous membranes, oral and ocular involvement can occur and is particularly troublesome. Oral ulcers may make eating or speaking difficult, while eye disease carries a small but real risk of visual complications. Clinicians must also differentiate EM from  Stevens-Johnson syndrome,  a more severe condition with significant systemic involvement.^1,3

EM is relatively uncommon, affecting fewer than 1% of the population, and most often occurs between ages 20 and 40, with men slightly more frequently affected than women. The most common trigger is the Herpes simplex virus, which appears to provoke an abnormal immune response against viral antigens in the skin.⁴ Mycoplasma pneumoniae is another recognised cause, usually accompanied by respiratory symptoms. Drugs or other infections are less common triggers.²

Treatment

Treatment focuses mainly on relieving symptoms and preventing recurrence. Topical corticosteroids and antihistamines are commonly used for mild cases. In recurrent herpes-associated EM, prophylactic antivirals may reduce flare frequency. Severe cases may require systemic therapy, intravenous fluids or immunosuppressive medications. However, no treatment is consistently effective for all patients, meaning many continue to experience cycles of flare, partial relief, and recurrence.^1,3

This helps explain why PROs and QoL measures are so important — they reflect the frustration and disruption of a condition that is unpredictable and only partly manageable. One case study described a 25-year-old man with herpes-associated EM assessed using the Oral Health Impact Profile-14 (OHIP-14). He reported painful oral ulcers leading to bleeding, difficulty eating and social withdrawal. After a week of treatment combining acyclovir, topical agents, and non-pharmacological advice such as avoiding spicy foods and improving oral hygiene, both his lesions and his QoL improved.⁵ Although this represents only one patient, it demonstrates the significant effect EM can have on everyday function.

However, larger studies rarely capture this perspective. A retrospective cohort of 35 patients with recurrent EM described disease course and treatment strategies but did not include QoL assessment.⁶ Likewise, a systematic review of EM interventions reported that almost none of the included studies evaluated QoL.⁷ As early as 1983, Bean and Quezada referred to patients with recurring oral EM as experiencing “considerable morbidity,” yet without structured QoL measurement.⁸ This shows that under-reporting of patient experience has been present for more than four decades.

The consequences for patients are significant. Pain, oral dysfunction and treatment side effects can make daily activities challenging. Severe oral involvement may contribute to malnutrition or weight loss, while visible lesions can lead to stigma, anxiety and social withdrawal. Individuals may miss school or work during flares, adding extra disruption.^5-8 Alongside this, repeated medication cycles — antivirals, corticosteroids or systemic agents — may be burdensome and not always successful.

Summary

EM is a rare but impactful condition characterised by target-like skin lesions and, in some cases, painful mucosal involvement. While triggers and disease patterns are increasingly recognised, the patient perspective remains underrepresented in research. The few available reports suggest that EM disrupts eating, speaking, social interaction and psychological well-being, yet most clinical studies do not include validated PRO or QoL measures. To improve management and therapy development, future work must integrate PRO data so that clinical and lived experiences are valued equally.